HIV infection HIV infection, In combination with Rilpivirine to replace current stable ARV regimen
Monitor viral load, CD4 cell counts, and hepatitis B screening at baseline and with modification of ARV treatment.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT, AST, total bilirubin, and urinalysis at baseline and with modification of ARV treatment.
Obtain fasting blood glucose or HbA1C, fasting lipid profile, and CBC with a differential.
Obtain basic chemistry including serum sodium, potassium, bicarbonate, chloride, BUN, creatinine, and creatinine-based estimated glomerular filtration rate.
Common
Serious
Contraindication:
Major drug-drug interactions:
Antimicrobial class: Antiretroviral agent, HIV integrase strand transfer inhibitor
Average serum half life: 14 hours
Precautions: Use with caution in patients with severe renal impairment who are also integrase strand transfer inhibitor (INSTI) experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance; loss of therapeutic effect and development of resistance may occur due to decreased concentrations.
Monitor underlying hepatitis B or C, and hepatotoxicity.
Discontinue if hypersensitivity reactions develop.
항생제
